Pluripotent Stem Cell Induction via Small-Molecule and miR-290 Composition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for inducing pluripotent stem cells are inefficient and pose risks of genetic mutations due to the use of exogenous transcription factors linked to viruses.

Innovation Solution

A composition comprising miR-290 family microRNAs combined with specific small-molecule compounds, including valproic acid, RepSox, CHIR-99021, PD0325901, and tranylcypromine, is used to induce pluripotent stem cells without the need for exogenous transcription factors linked to viruses, thereby enhancing safety and efficiency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If exogenous transcription factors linked to viruses are used to induce pluripotent stem cells, then reprogramming can be achieved, but genetic mutations occur and safety is compromised

Engineering Contradiction:

Improvesafety of iPS cell preparationVSAvoidgenetic mutations

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts and removes the harmful viral vector component from the reprogramming process. Instead of using viral delivery of transcription factors, the invention uses small-molecule compounds that directly induce pluripotency without requiring viral integration, thereby eliminating the source of genetic mutations while maintaining reprogramming capability

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent replaces the biological/mechanical system of viral transcription factor delivery with a chemical system using small-molecule compounds. The small molecules (such as valproic acid, CHIR99021, PD0325901, RepSox, and tranylcypromine) substitute for the viral mechanism, achieving reprogramming through chemical modulation of cellular pathways rather than genetic manipulation

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If conventional small-molecule compounds are used to induce pluripotent stem cells, then the process can be simplified, but reprogramming efficiency remains low

Engineering Contradiction:

Improvereprogramming efficiencyVSAvoidcomplexity of induction composition

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent merges multiple small-molecule compounds into a synergistic combination formula. The composition includes valproic acid (HDAC inhibitor), CHIR99021 (GSK-3 inhibitor), PD0325901 (MEK inhibitor), RepSox (TGF-βR1 inhibitor and histone demethylase inhibitor), and tranylcypromine (LSD1 inhibitor). This combination leverages the complementary mechanisms of each compound to achieve high reprogramming efficiency that none of the individual compounds could achieve alone

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent creates a composite induction composition where multiple small-molecule compounds work together synergistically. Each compound targets different molecular pathways (histone modification, kinase signaling, demethylase activity), and their combined effect produces a reprogramming efficiency that exceeds the sum of individual effects, analogous to composite materials where combined properties create superior performance

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively induces somatic cells into induced pluripotent stem cells, improving reprogramming efficiency and safety by preventing genetic mutations, and demonstrates the ability to differentiate into various cell types and improve myocardial function in mice with myocardial infarction.

Implementation Method 1

valproic acid (a histone deacetylase inhibitor)

Methodology Applied

Scientific EffectHistone deacetylase inhibition:

Implementation Method 2

RepSox (E-616452, a transforming growth factor beta receptor 1 inhibitor and a histone demethylase inhibitor)

Methodology Applied

Scientific EffectTransforming growth factor beta receptor 1 inhibition:

Implementation Method 3

RepSox (E-616452, a transforming growth factor beta receptor 1 inhibitor and a histone demethylase inhibitor)

Methodology Applied

Scientific EffectHistone demethylase inhibition:

Implementation Method 4

CHIR-99021 (a glycogen synthase kinase-3 inhibitor)

Methodology Applied

Scientific EffectGlycogen synthase kinase-3 inhibition:

Implementation Method 5

PD0325901 (a mitogen-activated extracellular signal-regulated kinase inhibitor)

Methodology Applied

Scientific EffectMitogen-activated extracellular signal-regulated kinase inhibition:

Implementation Method 6

tranylcypromine (an inhibitor of LSD1 histone demethylase and monoamine oxidases (MAO))

Methodology Applied

Scientific EffectLSD1 histone demethylase inhibition:

Implementation Method 7

miRNAs can be coupled with target mRNAs through base pairing to activate RNA-induced silencing complex (RISC) that degrades mRNAs or prevents mRNAs from being translated

Methodology Applied

Scientific EffectRNA interference:

Data Source

PatentUS20240392253A1Composition for induction of pluripotent stem cell

Publication Date: 2024.11.28 GMU MEDICAL DRUG DEV CO LTD

AI summary

A composition for induction of a pluripotent stem cell including a microRNA and a combination of small-molecule compounds. The microRNA includes one of the miR-290 family members, or a microRNA sequence having at least 90% identity with a sequence of one of the miR-290 family members. The combination of small-molecule compounds includes a histone deacetylase inhibitor, a mitogen-activated extracellular signal-regulated kinase inhibitor, a glycogen synthase kinase-3 inhibitor, a transforming growth factor beta receptor 1 (TGF-βR1) inhibitor, and an inhibitor of histone demethylase.